Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Colorectal cancer vaccine - Oryx GmbH & Co.

Drug Profile

Colorectal cancer vaccine - Oryx GmbH & Co.

Alternative Names: Frameshift peptide colorectal cancer vaccine; FSP colorectal cancer vaccine; MicOryx; Vaccine MSI - Oryx

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oryx GmbH & Co
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 07 Jan 2016 Colorectal cancer vaccine is available for licensing before Jan 2016. http://www.oryx-medicine.com
  • 22 Sep 2015 Phase I/II development is ongoing in Germany
  • 04 Mar 2015 Oryx GmbH completes a phase I/II trial in Colorectal cancer in Germany (NCT01461148,
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top